GlassScriptPhysician profile
Intazam Uddin Khan
NPI 1548352594
$47,395.80
in general payments reported to CMS, 2019-2025
57 companies · $9,763 in 2025
The $9,763 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,736 · 2020: $1,567 · 2021: $12K · 2022: $5,606 · 2023: $12K · 2024: $3,288 · 2025: $9,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $10K · Education: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,050.00 |
| Food and Beverage | $10,161.79 |
| Education | $588.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,827.70 | 2021-2025 | |
| Pfizer INC. | $7,334.29 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,206.30 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Allergan, INC. | $1,779.12 | 2020-2021 | |
| Ucb, INC. | $1,618.45 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Livanova USA, INC. | $1,564.00 | 2019-2020 | |
| Biogen, INC. | $1,280.32 | 2019-2024 | Tysabri, Vumerity |
| Scilex Pharmaceuticals INC. | $874.48 | 2021-2025 | Ztlido |
| Genzyme Corporation | $762.05 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $698.21 | 2020-2025 | Ingrezza, Ongentys |
| Ani Pharmaceuticals, INC. | $681.43 | 2022-2025 | Purified Cortrophin Gel |
| Eisai INC. | $670.28 | 2021-2025 | |
| Sk Life Science, INC. | $571.95 | 2020-2024 | Xcopri |
| Novartis Pharmaceuticals Corporation | $560.85 | 2019-2023 | |
| Lundbeck LLC | $470.85 | 2019-2025 | Vyepti |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Intazam Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.